Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
| Autor: | Yoshimichi Chuganji, Chisa Kondo, Katsuhiko Iwakiri, Norio Itokawa, Yohei Koushima, Tadashi Ikegami, Toru Asano, Masanori Atsukawa, Shinichi Sato, Akihito Tsubota, Kouji Watanabe, Shigeru Mikami, Tomomi Okubo, Taeang Arai, Noritomo Shimada, Keizo Kato, Hiroshi Abe, Yasushi Matsuzaki |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Hepatology Combination therapy business.industry medicine.medical_treatment Pharmacology Gastroenterology Ombitasvir End stage renal disease 03 medical and health sciences 0302 clinical medicine Infectious Diseases Paritaprevir Internal medicine Ombitasvir/paritaprevir/ritonavir medicine 030211 gastroenterology & hepatology Ritonavir 030212 general & internal medicine business Adverse effect Dialysis medicine.drug |
| Zdroj: | Hepatology Research. 47:1429-1437 |
| ISSN: | 1386-6346 |
| DOI: | 10.1111/hepr.12910 |
| Popis: | Aim From a pharmacokinetic viewpoint, ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this study was to assess the efficacy and safety that have not yet been addressed in patients undergoing dialysis. Methods A retrospective, multicenter study evaluated the outcome of 12-week ombitasvir (NS5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir combination therapy for dialysis patients. The primary endpoint was sustained virologic response 12 weeks after therapy (SVR12). Results The subjects were 31 patients aged 63 years (range, 49–85 years) including 10 cirrhotic patients. All of the 31 patients had an estimated glomerular filtration rate level |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|